Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Operating Expenses (2016 - 2026)

Sunshine Biopharma filings provide 14 years of Operating Expenses readings, the most recent being $6.4 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 2.89% to $6.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.1 million, a 12.41% increase, with the full-year FY2025 number at $23.1 million, up 11.88% from a year prior.
  • Operating Expenses hit $6.4 million in Q4 2025 for Sunshine Biopharma, up from $5.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $24.9 million in Q4 2022 to a low of $397842.0 in Q4 2021.
  • Median Operating Expenses over the past 5 years was $4.4 million (2023), compared with a mean of $4.6 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 6161.52% in 2022 and later crashed 78.74% in 2023.
  • Sunshine Biopharma's Operating Expenses stood at $397842.0 in 2021, then surged by 6161.52% to $24.9 million in 2022, then tumbled by 78.74% to $5.3 million in 2023, then rose by 16.59% to $6.2 million in 2024, then increased by 2.89% to $6.4 million in 2025.
  • The last three reported values for Operating Expenses were $6.4 million (Q4 2025), $5.0 million (Q3 2025), and $6.6 million (Q2 2025) per Business Quant data.